Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Trial details
- Registry ID
- NCT03608033
- Drugs studied
- OMS721, Vehicle (D5W or saline)
TrialRedline tracks 8 clinical trials sponsored by Omeros Corporation: 2 Phase 3, 6 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyNCT03608033 | OMS721, Vehicle (D5W or saline) | Terminated | 2024-01-12Actual |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeNCT03205995 | OMS721 (narsoplimab) | Terminated | 2021-02-02Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMANCT05855083 | Biological: narsoplimab | Recruiting | 2025-12Estimated |
| Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaNCT06298955 | OMS906 study drug | Active not recruiting | 2026-12Estimated |
| Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabNCT05972967 | OMS906 | Completed | 2024-10-10Actual |
| Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesNCT02222545 | OMS721 | Completed | 2020-01-30Actual |
| Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNNCT06209736 | OMS906 study drug | Terminated | 2026-04-14Actual |
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721NCT02682407 | OMS721 (narsoplimab) | Terminated | 2020-08-25Actual |
Names as written in the registry records.
NCT06209736 · Omeros Corporation
Before: Estimated. After: Actual.
Before: 20 participants (planned). After: 3 participants (actual).
Before: Estimated. After: Actual.
Before: Jan 2026. After: 14 Apr 2026.
Before: Recruiting. After: Terminated.
NCT06298955 · Omeros Corporation
Before: Recruiting. After: Active not recruiting.
NCT02682407 · Omeros Corporation
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy subjects with treatment related adverse events (AE). Measure: Cohort 4: Proportion of IgAN patients of Asian descent with treatment related AEs. Measure: Cohort 4: Change from baseline in serum and urine complement component levels.. After: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). Measure: Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs. Measure: Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels..
Before: Estimated. After: Actual.
Before: 54 participants (planned). After: 31 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2020. After: 25 Aug 2020.
Before: Recruiting. After: Terminated.